
    
      Physicians will record information (from the time of first exposure to pegylated interferon
      alfa-2b and ribavirin) from the medical notes of participants who fit the inclusion criteria.
      To prevent selection bias, data are to be taken from the latest consecutive, unique
      participants seen by the physician over the previous 48 months. This provides a method of
      random sampling from a physician practice.
    
  